Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate

Loading...
Publication Logo

Date

2018

Journal Title

Journal ISSN

Volume Title

Publisher

Pergamon-Elsevier Science Ltd

Open Access Color

Green Open Access

No

OpenAIRE Downloads

OpenAIRE Views

Publicly Funded

No
Impulse
Average
Influence
Average
Popularity
Top 10%

Research Projects

Journal Issue

Abstract

Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT.

Description

Keywords

ADHD, DAT1 gene, [Tc-(99m)] TRODAT-1 SPECT, OROS-methylphenidate, Deficit Hyperactivity Disorder, Dopamine-Transporter Gene, Attention-Deficit/Hyperactivity Disorder, Tc-99m-Trodat-1 Spect, Parkinsons-Disease, Children, Association, Adults, Psychostimulants, Availability, Male, Adolescent, OROS-methylphenidate, ADHD, Humans, Genetic Predisposition to Disease, DAT1 gene, [Tc-(99m)] TRODAT-1 SPECT, Psychiatric Status Rating Scales, Tomography, Emission-Computed, Single-Photon, Brain Mapping, Dopamine Plasma Membrane Transport Proteins, Homozygote, Brain, Organotechnetium Compounds, Treatment Outcome, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Methylphenidate, Central Nervous System Stimulants, Female, Radiopharmaceuticals, Tropanes

Fields of Science

03 medical and health sciences, 0302 clinical medicine

Citation

WoS Q

Q1

Scopus Q

Q1
OpenCitations Logo
OpenCitations Citation Count
8

Source

Progress in Neuro-Psychopharmacology & Bıologıcal Psychıatry

Volume

86

Issue

Start Page

294

End Page

300
PlumX Metrics
Citations

CrossRef : 8

Scopus : 7

PubMed : 5

Captures

Mendeley Readers : 38

SCOPUS™ Citations

7

checked on Mar 22, 2026

Web of Science™ Citations

6

checked on Mar 22, 2026

Page Views

9

checked on Mar 22, 2026

Google Scholar Logo
Google Scholar™
OpenAlex Logo
OpenAlex FWCI
0.4875

Sustainable Development Goals